 |
0 Diseases |  |
18 Trials |
|
18 Trials |  |
157 News |  |
| «123456» |
- | oleclumab (MEDI9447) / AstraZeneca, monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial (clinicaltrials.gov) - Jul 23, 2020
P1, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2020 --> Aug 2021 | Trial primary completion date: Jul 2020 --> Aug 2021 | Suspended --> Recruiting
- | oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy: A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) (clinicaltrials.gov) - Jul 22, 2020
P1, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Jul 2020 --> Aug 2021 | Trial primary completion date: Jul 2020 --> Aug 2021 | Suspended --> Recruiting Trial completion date: Jun 2021 --> Jul 2022 | Trial primary completion date: Jun 2020 --> Jul 2021
- oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, paclitaxel / Generic mfg.
[VIRTUAL] First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC) (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_666;
P1/2
Funding: AstraZeneca. Clinical trial identification: EudraCT: 2017-004651-23; Sponsor Protocol Number: IJB-SYNERGY-012017; NCT03616886.
- ||| Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Combination therapy: NeoCOAST: Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 14, 2020
P2, N=160, Recruiting, Sponsor: MedImmune LLC
Clinical trial identification: EudraCT: 2017-004651-23; Sponsor Protocol Number: IJB-SYNERGY-012017; NCT03616886. Active, not recruiting --> Recruiting
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Combination therapy, PD(L)-1 Biomarker, Metastases: D6070C00001: MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors. (clinicaltrials.gov) - Jul 9, 2020
P1, N=190, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Recruiting N=348 --> 190
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Trial completion date, Trial primary completion date: Neo-CheckRay: Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (clinicaltrials.gov) - Jun 9, 2020
P2, N=147, Active, not recruiting, Sponsor: Jules Bordet Institute
N=348 --> 190 Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Jun 2022 --> Oct 2022
- || oleclumab (MEDI9447) / AstraZeneca, monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial initiation date, Combination therapy: Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC (clinicaltrials.gov) - May 15, 2020
P2, N=160, Not yet recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Jun 2022 --> Oct 2022 Initiation date: Apr 2020 --> Oct 2020
- || oleclumab (MEDI9447) / AstraZeneca
Enrollment closed, Combination therapy, Metastases: Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study (clinicaltrials.gov) - May 6, 2020
P1b/2, N=98, Active, not recruiting, Sponsor: MedImmune LLC
Initiation date: Apr 2020 --> Oct 2020 Recruiting --> Active, not recruiting
- oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, BMS, gemcitabine / Generic mfg.
PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) PATIENT-DERIVED TUMOR ORGANOID (PDTO) GENERATION BY EUS-FNB IS FEASIBLE IN PATIENTS PREVIOUSLY TREATED WITH CHEMOTHERAPY () - May 4, 2020 - Abstract #DDW2020DDW_4310;
Precision medicine-based management options using PDTO may exist for all patients with PDAC irrespective of stage or treatment status. Future larger prospective studies will be required to study factors predictive of PDTO success in both treatment-naïve and previously treated patients.
- || Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Combination therapy: NeoCOAST: Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 30, 2020
P2, N=160, Active, not recruiting, Sponsor: MedImmune LLC
Future larger prospective studies will be required to study factors predictive of PDTO success in both treatment-naïve and previously treated patients. Recruiting --> Active, not recruiting
- || Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) - Apr 30, 2020
P1, N=257, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Oct 2023 | Trial primary completion date: Dec 2020 --> Oct 2023
- || Biomarker, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: HUDSON: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (clinicaltrials.gov) - Apr 30, 2020
P2, N=320, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Oct 2023 | Trial primary completion date: Dec 2020 --> Oct 2023 Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
Enrollment open, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Apr 28, 2020
P1, N=204, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022 Active, not recruiting --> Recruiting
- || imaradenant (AZD4635) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, Metastases: A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Apr 24, 2020
P1, N=307, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Recruiting Trial completion date: Oct 2020 --> Mar 2021 | Trial primary completion date: Oct 2020 --> Mar 2021
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
Enrollment closed, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Apr 23, 2020
P1, N=204, Active, not recruiting, Sponsor: MedImmune LLC
Trial completion date: Oct 2020 --> Mar 2021 | Trial primary completion date: Oct 2020 --> Mar 2021 Recruiting --> Active, not recruiting
- | oleclumab (MEDI9447) / AstraZeneca, monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial suspension, Metastases: Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial (clinicaltrials.gov) - Apr 14, 2020
P1, N=24, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Suspended
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Combination therapy, Metastases: COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov) - Apr 14, 2020
P1b/2, N=112, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Suspended Recruiting --> Active, not recruiting
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: D6070C00001: MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors. (clinicaltrials.gov) - Apr 1, 2020
P1, N=348, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Trial completion date: Jul 2021 --> Jun 2022 | Trial primary completion date: Jul 2021 --> Jun 2022
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
Enrollment open, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Mar 12, 2020
P1, N=204, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Jul 2021 --> Jun 2022 | Trial primary completion date: Jul 2021 --> Jun 2022 Not yet recruiting --> Recruiting
- | Enrollment open, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases, Immuno-oncology: PIONeeR: Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (clinicaltrials.gov) - Mar 4, 2020
P2, N=120, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Mar 2023 --> Oct 2023
- oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, BMS
First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 Oleclumab (O) to the anti-PD-L1 Durvalumab (D) and Chemotherapy (ChT) as 1st line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC) (Exhibition area) - Mar 4, 2020 - Abstract #ESMOBC2020ESMO_BC_383;
- || oleclumab (MEDI9447) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study (clinicaltrials.gov) - Mar 2, 2020
P1b/2, N=98, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Mar 2023 --> Oct 2023 Trial completion date: Jul 2022 --> Oct 2022 | Trial primary completion date: Jul 2022 --> Oct 2022
- | Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Combination therapy, Metastases: BEGONIA: A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 25, 2020
P1/2, N=110, Recruiting, Sponsor: AstraZeneca
Trial completion date: Jul 2022 --> Oct 2022 | Trial primary completion date: Jul 2022 --> Oct 2022 Trial completion date: Jun 2021 --> Nov 2021
- || Clinical, P1 data, P2 data, Journal: SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). (Pubmed Central) - Feb 23, 2020
Trial completion date: Jun 2021 --> Nov 2021 No abstract available
- ||| oleclumab (MEDI9447) / AstraZeneca, AZD4635 / AstraZeneca, MEDI7247 / AstraZeneca
$AZN discontinuations: MEDI7247 (anti-ASCT2 ADC) & oleclumab+AZD4635 combo (CD73+A2A inh, relevant to $CRVS ) (Twitter) - Feb 14, 2020
- |||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, Epigenetic controller: DOMINATION: A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (clinicaltrials.gov) - Feb 9, 2020
P2, N=55, Not yet recruiting, Sponsor: University Health Network, Toronto
- |||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, Epigenetic controller: DOME: A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (clinicaltrials.gov) - Feb 9, 2020
P2, N=120, Not yet recruiting, Sponsor: University Health Network, Toronto
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
New P1 trial, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Feb 6, 2020
P1, N=204, Not yet recruiting, Sponsor: MedImmune LLC
- || oleclumab (MEDI9447) / AstraZeneca, monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial initiation date, Combination therapy: Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC (clinicaltrials.gov) - Feb 5, 2020
P2, N=160, Not yet recruiting, Sponsor: MedImmune LLC
No abstract available Initiation date: Jan 2020 --> Apr 2020
- || imaradenant (AZD4635) / AstraZeneca
Trial completion date, Trial primary completion date: An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer (clinicaltrials.gov) - Jan 27, 2020
P2, N=60, Recruiting, Sponsor: AstraZeneca
Initiation date: Jan 2020 --> Apr 2020 Trial completion date: Mar 2021 --> Oct 2021 | Trial primary completion date: Mar 2021 --> Oct 2021
- || Biomarker, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: HUDSON: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (clinicaltrials.gov) - Jan 6, 2020
P2, N=320, Recruiting, Sponsor: AstraZeneca
Trial completion date: Mar 2021 --> Oct 2021 | Trial primary completion date: Mar 2021 --> Oct 2021 Trial completion date: Jul 2021 --> Sep 2022 | Trial primary completion date: Jul 2021 --> Sep 2022
- Imfinzi (durvalumab) / AstraZeneca, BMS
Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2. (Poster Board J8) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_1243;
P1
Toxicities are consistent with data from other PD-1/PD-L1 inhibitor trials. Future cohorts will examine D-containing combination NAT strategies.
- Imfinzi (durvalumab) / AstraZeneca, BMS
Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2. (Poster Board J8) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_961;
P1
Toxicities are consistent with data from other PD-1/PD-L1 inhibitor trials. Future cohorts will examine D-containing combination NAT strategies.
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Combination therapy, PD(L)-1 Biomarker, Metastases: D6070C00001: MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors. (clinicaltrials.gov) - Dec 9, 2019
P1, N=348, Active, not recruiting, Sponsor: MedImmune LLC
Future cohorts will examine D-containing combination NAT strategies. Recruiting --> Active, not recruiting
- || oleclumab (MEDI9447) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study (clinicaltrials.gov) - Dec 9, 2019
P1b/2, N=98, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Mar 2022 --> Jul 2022
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Combination therapy, Metastases: D6070C00005: MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. (clinicaltrials.gov) - Dec 5, 2019
P1b/2, N=310, Active, not recruiting, Sponsor: MedImmune LLC
Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Mar 2022 --> Jul 2022 Recruiting --> Active, not recruiting
- | oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy: A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) (clinicaltrials.gov) - Nov 15, 2019
P1, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Jun 2020
- |||| oleclumab (MEDI9447) / AstraZeneca, monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, Combination therapy: Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC (clinicaltrials.gov) - Nov 14, 2019
P2, N=160, Not yet recruiting, Sponsor: MedImmune LLC
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment open: Neo-CheckRay: Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (clinicaltrials.gov) - Nov 8, 2019
P2, N=147, Recruiting, Sponsor: Jules Bordet Institute
Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Jun 2020 Not yet recruiting --> Recruiting
- | imaradenant (AZD4635) / AstraZeneca
New P2 trial: An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer (clinicaltrials.gov) - Sep 12, 2019
P2, N=60, Recruiting, Sponsor: AstraZeneca
- | imaradenant (AZD4635) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, Metastases: A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Aug 9, 2019
P1, N=295, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Trial completion date: Jun 2020 --> Oct 2020 | Trial primary completion date: Jun 2020 --> Oct 2020
- | oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: D6070C00001: MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors. (clinicaltrials.gov) - Jul 18, 2019
P1, N=348, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Jun 2020 --> Oct 2020 | Trial primary completion date: Jun 2020 --> Oct 2020 Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: D6070C00005: MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. (clinicaltrials.gov) - Jul 8, 2019
P1b/2, N=309, Recruiting, Sponsor: MedImmune LLC
Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021 N=204 --> 309 | Trial completion date: Apr 2021 --> Nov 2021 | Trial primary completion date: Apr 2021 --> Nov 2021
- || oleclumab (MEDI9447) / AstraZeneca
Trial completion, Metastases: A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients (clinicaltrials.gov) - Jul 8, 2019
P1, N=6, Completed, Sponsor: AstraZeneca
N=204 --> 309 | Trial completion date: Apr 2021 --> Nov 2021 | Trial primary completion date: Apr 2021 --> Nov 2021 Active, not recruiting --> Completed
- | Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Combination therapy, Metastases: BEGONIA: A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 5, 2019
P1/2, N=110, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Trial completion date: Dec 2020 --> Jun 2021
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: D6070C00001: MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors. (clinicaltrials.gov) - Apr 29, 2019
P1, N=310, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Dec 2020 --> Jun 2021 Trial completion date: Oct 2020 --> May 2020 | Trial primary completion date: Oct 2020 --> May 2020
- || Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: COAST: Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (clinicaltrials.gov) - Apr 16, 2019
P2, N=300, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Oct 2020 --> May 2020 | Trial primary completion date: Oct 2020 --> May 2020 Trial completion date: Apr 2023 --> Sep 2023 | Trial primary completion date: Apr 2023 --> Sep 2023
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Now open at @MDAndersonNews https://t.co/SELNIhTFrc Oleclumab (anti-CD73) +/- Durvalumab plus chemoRx in metastatic #PancreaticCancer Cc: @CancerMedMDA @michael_overman @drspant (Twitter) - Apr 10, 2019
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: D6070C00001: MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors. (clinicaltrials.gov) - Apr 8, 2019
P1, N=310, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Apr 2023 --> Sep 2023 | Trial primary completion date: Apr 2023 --> Sep 2023 Trial completion date: Feb 2021 --> Oct 2020 | Trial primary completion date: Feb 2021 --> Oct 2020
- | oleclumab (MEDI9447) / AstraZeneca, monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Metastases: Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial (clinicaltrials.gov) - Apr 2, 2019
P1, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Feb 2021 --> Oct 2020 | Trial primary completion date: Feb 2021 --> Oct 2020 Suspended --> Recruiting